

Appn. Number 10/717,162 (Sung et al.) GAU 1614 Amnt. A contd. 3 of 7

RECEIVED
CENTRAL FAX CENTER**OCT 10 2007****AMENDMENTS TO THE CLAIMS:**

Please cancel claims 5-6, 10 and 21-41 from further consideration. Please amend claims 2-3, 7-8, and 11-18.

A complete listing of all claims and their current status is presented below.

1(original). A medical device, comprising:

a biodegradable apparatus having a surface;

at least one bioactive agent; and

biological material loaded onto at least a portion of the surface of said apparatus, said biological material comprising said at least one bioactive agent, wherein said biological material is crosslinked with a crosslinking agent or with ultraviolet irradiation.

2(currently amended). The device of claim 1, wherein the crosslinking agent is genipin, ~~its analog, derivatives, and combination thereof.~~

3(currently amended). The device of claim 1, wherein the crosslinking agent ~~is selected from a group consisting of formaldehyde, glutaraldehyde, dialdehyde starch, glyceraldehydes, cyanamide, diimides, diisocyanates, dimethyl adipimidate, carbodiimide, comprises an epoxy compound, and mixture thereof.~~

4(original). The device of claim 1, wherein the apparatus is a stent.

5-6(cancelled).

7(currently amended). The device of claim 1, wherein the biological material ~~is selected from a group consisting of collagen, gelatin, elastin, chitosan, N, O, carboxymethyl chitosan, and mixture thereof.~~

Appn. Number 10/717,162 (Sung et al.) GAU 1614 Amnt. A contd. 4 of 7

8(currently amended). The device of claim 1, wherein the biological material is a solidifiable substrate, and wherein the biological material is solidifiable from a phase ~~selected from a group consisting of solution, paste, gel, suspension, colloid, and plasma.~~

9(original). The device of claim 1, wherein the biodegradable apparatus is made of a material selected from a group consisting of polylactic acid (PLA), polyglycolic acid (PGA), poly (D,L-lactide-co-glycolide), polycaprolactone, and co-polymers thereof.

10(cancelled).

11(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent is ~~selected from a group consisting of analgesics/antipyretics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, antiplatelet agents and antibacterial agents, antiviral agents, antimicrobials, and anti-infectives~~ for treating pain or lowering body temperature from a raised state.

12(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent is selected from a group consisting of actinomycin D, paclitaxel, vincristin, methotrexate, and angiopeptin, batimastat, halofuginone, sirolimus, tacrolimus, everolimus, tranilast, dexamethasone, and mycophenolic acid for treating atherosclerotic plaque.

13(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent comprises ~~is selected from a group consisting of lovastatin, thromboxane A₂ synthetase inhibitors, eicosapentanoic acid, ciprostone, trapidil, angiotensin-converting enzyme inhibitors, aspirin, and heparin~~ for lowering cholesterol in a patient with hypercholesterolemia.

Appn. Number 10/717,162 (Sung et al.) GAU 1614 Amnt. A contd. 5 of 7

14(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent ~~comprises is selected from a group consisting of allicin, ginseng extract, flavone, ginkgo biloba extract, glycyrrhethinic acid, and proanthocyanides~~ for treatment of peptic ulcer.

15(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent comprises ApoA-I Milano or recombinant ApoA-I Milano/phospholipid complexes for treating atherosclerotic plaque.

16(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent comprises biological cells for inducing cell proliferation.

17(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent comprises lipostabil for fat removal from a patient.

18(currently amended). The device of claim 1 ~~or 10~~, wherein the at least one bioactive agent comprises a growth factor for stimulating cellular proliferation and cellular differentiation.

19(original). The device of claim 18, wherein the growth factor is selected from a group consisting of vascular endothelial growth factor, transforming growth factor-beta, insulin-like growth factor, platelet derived growth factor, fibroblast growth factor, and combination thereof.

20(original). The device of claim 1 further comprising a biodegradable polymer loaded onto at least a portion of the surface of said apparatus.

20(cancelled). ~~A biodegradable medical device comprising at least one bioactive agent selected from a group consisting of ApoA-I Milano, recombinant ApoA-I Milano/phospholipid complexes, lipostabil, and combination thereof.~~

21-41(cancelled).